Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Sponsor: Eli Lilly and Company
Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Official title: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Key Details
Gender
All
Age Range
2 Years - 21 Years
Study Type
INTERVENTIONAL
Enrollment
71
Start Date
2020-06-11
Completion Date
2026-08
Last Updated
2025-07-23
Healthy Volunteers
No
Conditions
Interventions
LY3295668 Erbumine
Administered orally.
Topotecan
Administered IV.
Cyclophosphamide
Administered IV.
Locations (17)
UCSF Medical Center at Mission Bay
San Francisco, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
University of Chicago - Comer Children's Hospital
Chicago, Illinois, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Cincinnati Childrens Hospital Medical Center
Cincinnati, Ohio, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Texas Childrens Hospital
Houston, Texas, United States
Perth Children's Hospital
Perth, Western Australia, Australia
UZ Gent
Ghent, Oost-Vlaanderen, Belgium
Centre Leon Berard
Lyon, Auvergne-Rhône-Alpes, France
Institut Curie
Paris, France
Universitätsklinikum Köln
Cologne, Germany
Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Alder Hey Children's Hospital
Liverpool, United Kingdom